CD8A and neoplasm: prepared AuNDs@aPD-1, which not only exhibits long-term retention of drugs and enhancing the tumor-targeting ability, but also efficiently promotes the activation of antitumor CD4+ and CD8+ T cells, and inhibit the Treg cells activity in tumor when combined with PTT, showing significant anticancer ability to local as well as distant tumors (Figures 2C, D) (He et al., 2022).